-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Livmoniplimab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Livmoniplimab (ABBV-151) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Tislelizumab (Baizean) is a humanized monoclonal antibody...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SAR-444200 in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SAR-444200 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: SAR-444200 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INCB-099280 in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. INCB-099280 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: INCB-099280 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VG-161 in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VG-161 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: VG-161 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XmAb-662 in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.XmAb-662 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Xmab-662 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Sitravatinib malate is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Metastatic Hepatocellular Carcinoma (HCC)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tiragolumab in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tiragolumab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Tiragolumab (RG-6058, MTIG-7192A, anti-TIGIT) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Metastatic Hepatocellular Carcinoma (HCC)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Elzovantinib (TPX-0022) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Casdozokitug in Metastatic Hepatocellular Carcinoma (HCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Casdozokitug in Metastatic Hepatocellular Carcinoma (HCC)Drug Details:Casdozokitug (SRF-388) is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Codrituzumab in Metastatic Hepatocellular Carcinoma (HCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Codrituzumab in Metastatic Hepatocellular Carcinoma (HCC)Drug Details:Codrituzumab (RG-7686, GC-33, RO-5137382) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ezurpimtrostat in Metastatic Hepatocellular Carcinoma (HCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ezurpimtrostat in Metastatic Hepatocellular Carcinoma (HCC) Drug Details:Ezurpimtrostat (GNS-561) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cirtuvivint in Metastatic Hepatocellular Carcinoma (HCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Cirtuvivint in Metastatic Hepatocellular Carcinoma (HCC) Drug Details:SM-08502 is under development for the treatment of castration-resistant...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tocilizumab in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tocilizumab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Tocilizumab (Actemra / Roactemra) is a humanized...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Metastatic Hepatocellular Carcinoma (HCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Metastatic Hepatocellular Carcinoma (HCC) Drug Details:Plogosertib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ascrinvacumab in Metastatic Hepatocellular Carcinoma (HCC)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ascrinvacumab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Ascrinvacumab (PF-03446962) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: PRS-342 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Metastatic Hepatocellular Carcinoma (HCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: MHB-088C is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.